 NDA for ZIMHITM submitted to the FDA; Phase 23 clinical trial preparation initiated for Tempol for treatment of COVID-19 NDA for ZIMHITM submitted to the FDA; Phase 23 clinical trial preparation initiated for Tempol for treatment of COVID-19 